Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Connect MM- The Multiple Myeloma Disease Registry

Trial Profile

Connect MM- The Multiple Myeloma Disease Registry

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Dec 2018 Results assessing the treatment choices and outcomes for patients with MM after relapse on Lenalidomide Maintenance Therapy, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top